Skip to main content
Clinical Trials/NCT05041582
NCT05041582
Not yet recruiting
Phase 3

Combining SSRIs and TDCS to Enhance Motor Recovery After Stroke

Chih-Wei Tang0 sites80 target enrollmentSeptember 1, 2021

Overview

Phase
Phase 3
Intervention
tDCS
Conditions
Stroke
Sponsor
Chih-Wei Tang
Enrollment
80
Primary Endpoint
Motor scores 3 months after intervention
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

Post-stroke motor recovery is compelling but limited. Current rehabilitation has less impacts on the plateau that spontaneous biological recovery could be expected. The advances in non-invasive neuromodulation and neurophysiological characterization of critical motor recovery period enable breaking the proportional recovery limitation. Our pilot studies demonstrated the safety and responsiveness of combing dual transcranial direct current stimulation (tDCS) and motor training in subacute stroke patients. There is also strong evidence that selective serotonin reuptake inhibitors (SSRIs) can substantially increase the effects of tDCS and improve motor function after stroke, even in the absence of depression. This proposal aims to prove the potential of combining of tDCS and the commonly used SSRI citalopram to improve response to a daily motor training intervention in acute stroke patients (Co-STARS trial).

Detailed Description

This is a randomized, double-blind, sham-controlled study in 80 patients with first-ever, unilateral, subcortical ischemic stroke 0.5-4 weeks after stroke onset with moderate to severe hemiparesis. Participants were randomized into four groups underwent either real dual tDCS \[ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation; 2 mA for 20 mins; 10 sessions within 2 weeks\] with citalopram or placebo, or sham stimulation with citalopram or placebo. All will receive concurrent hospitalized intensive rehabilitation of 2 daily sessions of 90-minute physiotherapy. Action reach am test (ARAT), Fugl-Meyer Assessment (FMA), multimodality MRI and EEG will be measured at baseline and after 2 weeks' tDCS modulation. The primary outcome is the ARAT at 3 months after intervention. The combination of tDCS and a SSRI will be expected to improve response to motor training more effectively than either intervention alone. The enhanced responsiveness will be correlated or predicted by biomarkers from multimodality MRI or EEG.

Registry
clinicaltrials.gov
Start Date
September 1, 2021
End Date
August 31, 2025
Last Updated
4 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Sponsor
Chih-Wei Tang
Responsible Party
Sponsor Investigator
Principal Investigator

Chih-Wei Tang

Chief, Stroke Center

Far Eastern Memorial Hospital

Eligibility Criteria

Inclusion Criteria

  • aged 20-80;
  • first-onset stroke
  • brain image confirmed unilateral subcortical infarction
  • moderate to severe upper-limb impairment (SAFE score \<8).
  • 3 days to 4 weeks after stroke onset
  • stable medical condition

Exclusion Criteria

  • metal implants, such as electrodes or pacemaker
  • epilepsy history or active spikes from EEG recording
  • major depression or taking psychoactive drugs
  • alcoholism or drug abuse history
  • combined with other severe neurological or psychiatric diagnoses
  • pregnancy or breastfeeding;
  • other contraindications to brain MRI, such as severe claustrophobia
  • intolerance to electrical stimulation

Arms & Interventions

Real tDCS + Citalopram + Rehabilitation

* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks * Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: tDCS

Real tDCS + Citalopram + Rehabilitation

* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks * Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: Citalopram

Real tDCS + Citalopram + Rehabilitation

* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks * Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: Rehabilitation

Sham tDCS + Citalopram + Rehabilitation

* Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks * Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: Citalopram

Sham tDCS + Citalopram + Rehabilitation

* Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks * Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: Rehabilitation

Real tDCS + Placebo + Rehabilitation

* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks * Placebo oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: tDCS

Real tDCS + Placebo + Rehabilitation

* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks * Placebo oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: Rehabilitation

Sham tDCS + Placebo + Rehabilitation

* Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks * Placebo oral intake daily for 3 months, since 2 weeks before tDCS

Intervention: Rehabilitation

Outcomes

Primary Outcomes

Motor scores 3 months after intervention

Time Frame: 3 months after intervention

Motor scores include Action research arm test (0-66, higher scores mean a better outcome) and Fugl-Meyer Assessment (0-54, higher scores mean a better outcome)

Similar Trials